Cysteinyl leukotrienes in allergic inflammation: strategic target for therapy.

Published

Journal Article (Review)

Systemically bioavailable leukotriene receptor antagonists (LTRAs) can reduce the essential components of allergic inflammation in allergic rhinitis (AR) and asthma by blocking cysteinyl leukotriene (CysLT) activity, resulting in a wide range of clinical effects. CysLTs, mediators, and modulators in the pathophysiology of asthma and AR are a key target for therapy because they modulate production of hemopoietic progenitor cells, survival and recruitment of eosinophils to inflamed tissue, activity of cytokines and chemokines, quantity of exhaled NO, smooth-muscle contraction, and proliferation of fibroblasts. The mechanism of action of LTRAs leads to their effects on systemic allergic inflammatory processes.

Full Text

Cited Authors

  • Busse, W; Kraft, M

Published Date

  • April 2005

Published In

Volume / Issue

  • 127 / 4

Start / End Page

  • 1312 - 1326

PubMed ID

  • 15821210

Pubmed Central ID

  • 15821210

Electronic International Standard Serial Number (EISSN)

  • 1931-3543

International Standard Serial Number (ISSN)

  • 0012-3692

Digital Object Identifier (DOI)

  • 10.1378/chest.127.4.1312

Language

  • eng